Dupilumab: An emerging therapy in allergic fungal rhinosinusitis

Area of Science:

• Immunology
• Otolaryngology
• Pulmonology

Background:

• Allergic fungal rhinosinusitis (AFRS) presents significant treatment challenges, often proving resistant to conventional therapies.
• Patients experiencing recurrent AFRS, even after surgery, may benefit from biologic agents as supplementary treatments.
• Dupilumab has demonstrated positive outcomes in managing chronic rhinosinusitis with nasal polyposis (CRSwNP).

Purpose of the Study:

• To evaluate the efficacy of dupilumab as an adjunct therapy in patients with resistant allergic fungal rhinosinusitis (AFRS) and concomitant asthma.
• To assess the impact of dupilumab on both clinical symptoms and objective measures in this patient cohort.

Main Methods:

• This study presents a case series of four patients diagnosed with resistant AFRS and co-existing asthma.
• Dupilumab was administered as an adjunctive treatment to these patients.
• Long-term follow-up assessments were conducted.

Main Results:

• Dupilumab therapy led to significant improvement in the clinical symptoms of AFRS in all four patients.
• Objective measures, including imaging results (e.g., CT scans) and pulmonary function tests, showed notable enhancements post-treatment.
• The adjunctive use of dupilumab was well-tolerated by the patients.

Conclusions:

• Dupilumab can be an effective adjunctive therapy for patients suffering from treatment-resistant allergic fungal rhinosinusitis (AFRS) with asthma.
• The use of dupilumab offers a promising therapeutic option for improving both subjective and objective outcomes in complex AFRS cases.
• Further research with larger cohorts is warranted to confirm these findings and establish optimal treatment protocols.